Living with Wilson A patient-led project
A 文 English

← Back to all answers

treatment

What medications are used to treat Wilson disease?

Three classes are used — chelators (D-penicillamine, trientine) that pull copper out of the body, and zinc that blocks new copper absorption. The choice depends on disease stage, organ involvement, side-effect tolerance, and availability.

Written by the Living with Wilson team · Last reviewed 2026-04-26

Three medication classes form the backbone of Wilson disease treatment. They are lifelong — stopping treatment is the single biggest cause of preventable Wilson-disease death.1

D-penicillamine

The original Wilson disease drug, first reported by Walshe in 1956.2 It is a chelator — it binds copper in the blood and tissues so the kidneys can excrete it.

  • Strength: highly effective; more than six decades of evidence
  • Drawbacks: can paradoxically worsen neurological symptoms in some patients during early treatment;3 multiple long-term side effects affecting skin, kidneys, and bone marrow; requires vitamin B6 supplementation to prevent pyridoxine deficiency4
  • Dosing: taken on an empty stomach, typically split through the day; your physician will set the dose based on your weight and response

Trientine

A second-generation chelator originally developed for patients who could not tolerate D-penicillamine. Trientine is now often a preferred option, particularly for patients with neurological involvement, because accumulating evidence suggests it carries a somewhat lower risk of early neurological worsening.56

  • Strength: generally better tolerated than D-penicillamine
  • Drawbacks: historically expensive and not universally available; some formulations require refrigeration
  • Dosing: also taken on an empty stomach

A prospective cohort study comparing long-term outcomes of trientine versus D-penicillamine found that patients switched to trientine maintained copper control, supporting its use as an alternative or first-line agent.7

Zinc

Zinc is not a chelator. It works by blocking copper absorption in the gut: it stimulates a protein called metallothionein inside intestinal cells, which traps dietary copper and prevents it from entering the bloodstream. Those copper-laden cells are then shed naturally.8

  • Strength: very mild side-effect profile; excellent for maintenance therapy after an initial copper-depletion phase, and for pre-symptomatic patients identified through family screening4
  • Drawbacks: slower-acting; not strong enough alone when there is already significant copper overload in the body; can cause mild GI upset (often worst first thing in the morning)
  • Dosing: taken away from food and at least an hour away from any chelator

A comparison of zinc preparations for maintenance therapy found no meaningful difference in copper control between zinc acetate and other zinc salts, so availability and cost can guide the choice.9

Combinations and sequence

Most guidelines describe a two-phase approach:41

  1. Initial de-loading phase (roughly the first year): a chelator — penicillamine or trientine — to reduce accumulated copper stores
  2. Maintenance phase: transition to zinc, or continuation of a lower-dose chelator, based on how each patient responds

Some specialists use a chelator together with zinc from the start, staggered at different times of day so they do not cancel each other out. A prospective follow-up study found this combination produced adequate copper control in a majority of hepatic Wilson disease patients at two years.10

Where the AASLD 2022 guidelines and earlier EASL 2012 guidelines agree most clearly is on the principle: the regimen should be individualised, and any change should be guided by a physician experienced with the disease.41

Monitoring

Whatever the regimen, monitoring is not optional:

Test Why it matters
24-hour urinary copper Primary marker of treatment adequacy; target ranges differ for chelation vs. zinc maintenance
Serum non-ceruloplasmin-bound (“free”) copper Reflects exchangeable copper load; calculated from total copper and ceruloplasmin
Liver enzymes Track hepatic recovery and medication side effects
Routine bloodwork Catch chelator-related cytopenias, proteinuria, and other toxicities early

Long-term evaluation of urinary copper in patients on medical treatment shows that both 24-hour copper and non-ceruloplasmin-bound copper are useful, complementary markers, and that monitoring targets shift over the course of treatment.11

The AASLD 2022 guidelines recommend at minimum an annual (or more frequent) review with a hepatologist familiar with Wilson disease.4

On adherence

Wilson disease relapse from stopping medication can be fatal, sometimes presenting as acute liver failure with no warning.12 Build medication into your daily routine the way someone with type 1 diabetes builds in insulin: never optional, never skipped. If side effects or cost are making adherence hard, tell your medical team — there are options, and that conversation is far better than stopping quietly.

This article is for patient education only and does not replace advice from your own physician. Always discuss treatment changes with a healthcare professional who knows your case.

References

  1. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007 ↩↩↩

  2. Walshe, J.M. “Penicillamine, a new oral therapy for Wilson’s disease.” The American Journal of Medicine 21, no. 4 (1956): 487–495. https://doi.org/10.1016/0002-9343(56)90066-3 ↩

  3. Litwin, Tomasz, Anna Członkowska, and Lukasz Smolinski. “Early neurological worsening in Wilson disease: The need for an evidence-based definition.” Journal of Hepatology 79, no. 6 (2023): e241–e242. https://doi.org/10.1016/j.jhep.2023.06.009 ↩

  4. Schilsky, Michael L., Eve A. Roberts, Jeff M. Bronstein, and Anil Dhawan. “A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2022): E41–E90. https://doi.org/10.1002/hep.32801 ↩↩↩↩↩

  5. Członkowska, Anna, Tomasz Litwin, Petr Dusek, Peter Ferenci, Svetlana Lutsenko, Valentina Medici, Janusz K. Rybakowski, and Karl Heinz Weiss. “Wilson disease.” Nature Reviews Disease Primers 4 (2018): article 21. https://doi.org/10.1038/s41572-018-0018-3 ↩

  6. Ranjan, A., J. Kalita, V. Kumar, and U.K. Misra. “MRI and oxidative stress markers in neurological worsening of Wilson disease following penicillamine.” NeuroToxicology 49 (2015): 45–49. https://doi.org/10.1016/j.neuro.2015.05.004 ↩

  7. Weiss, K.H., J. Pfeiffenberger, W. Stremmel, R. Estall, and D.N. Gotthardt. “Prospective Study to Assess Long-Term Outcomes of Treatment with Trientine in Wilson Disease Patients Withdrawn from Therapy with D-Penicillamine.” Journal of Hepatology 64, suppl. 2 (2016): S105. https://doi.org/10.1016/s0168-8278(16)00368-8 ↩

  8. Brewer, George J. “Zinc therapy induction of intestinal metallothionein in Wilson’s disease.” American Journal of Gastroenterology 94, no. 2 (1999): 301–302. https://doi.org/10.1111/j.1572-0241.1999.00301.x ↩

  9. Camarata, Michelle A., Aftab Ala, and Michael L. Schilsky. “Zinc Maintenance Therapy for Wilson Disease: A Comparison Between Zinc Acetate and Alternative Zinc Preparations.” Hepatology Communications 3, no. 8 (2019): 1151–1158. https://doi.org/10.1002/hep4.1384 ↩

  10. Panda, Kalpana, Bikrant B. Lal, Vikrant Sood, Rajeev Khanna, and Seema Alam. “Adequate Chelation and Cupriuresis in Hepatic Wilson Disease Patients Under Combination (Chelator + Zinc) Therapy at 2 Years of Follow-up.” Journal of Clinical and Experimental Hepatology 14 (2024): 101284. https://doi.org/10.1016/j.jceh.2023.09.005 ↩

  11. Pfeiffenberger, Jan, Christine Marie Lohse, Daniel Gotthardt, Christian Rupp, and Markus Weiler. “Long-term evaluation of urinary copper excretion and non-caeruloplasmin associated copper in Wilson disease patients under medical treatment.” Journal of Inherited Metabolic Disease (2018). https://doi.org/10.1007/s10545-018-0218-8 ↩

  12. Litwin, Tomasz, Petr Dusek, and Anna Czlonkowska. “Neurological manifestations in Wilson’s disease — possible treatment options for symptoms.” Expert Opinion on Orphan Drugs 4, no. 7 (2016): 719–728. https://doi.org/10.1080/21678707.2016.1188003 ↩

This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.